MigVax receives funding award from CEPI to develop ‘variant-proof’ COVID-19 vaccines
04-11-2021
CEPI
We are honored to be one of the first two projects to receive funding from CEPI’s visionary program aimed at accelerating the development of broadly protective vaccines against coronaviruses and their variants